Paper16166314
Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy.
Pan Q and 6 others. Cancer Res, 2005. Cited by 121 papers, by iCite.
Cite this record
ConductScience Library. Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Papers, record 16166314. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16166314
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy.
- PubMed
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomarkers, Tumor | Major topic |
| Breast Neoplasms | Major topic |
| Protein Kinase C-epsilon | Major topic |
| Animals | |
| Carcinoma, Ductal, Breast | |
| Cell Growth Processes | |
| Cell Line, Tumor | |
| Disease-Free Survival | |
| Female | |
| Humans | |
| Mice | |
| Mice, Nude | |
| Predictive Value of Tests | |
| RNA Interference | |
| RNA, Small Interfering | |
| Xenograft Model Antitumor Assays | |
| ras Proteins | |
| rho GTP-Binding Proteins | |
| rhoC GTP-Binding Protein |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| M01-RR00042 | NCRR NIH HHS | United States | M01RR000042 | PubMed and NIH | NIH RePORTER |
| P30CA46592 | NCI NIH HHS | United States | P30CA046592 | PubMed and NIH | NIH RePORTER |
| P50CA97248 | NCI NIH HHS | United States | P50CA097248 | PubMed and NIH | NIH RePORTER |
| R01CA77612 | NCI NIH HHS | United States | R01CA077612 | PubMed and NIH | NIH RePORTER |
Cited by70
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 121 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41301871 | Toxicological Impacts and Mechanistic Insights of Bisphenol a on Clear Cell Renal Cell Carcinoma Progression: A Network Toxicology, Machine Learning and Molecular Docking Study. | Biomedicines | 2025 | https://conductscience.org/library/papers/41301871 | PubMed |
| 38042915 | Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets. | NPJ Breast Cancer | 2023 | https://conductscience.org/library/papers/38042915 | PubMed |
| 37667176 | Exploring the prognostic significance of PKCε variants in cervical cancer. | BMC Cancer | 2023 | https://conductscience.org/library/papers/37667176 | PubMed |
| 37645595 | Protein kinase C epsilon activation regulates proliferation, migration, and epithelial to mesenchymal-like transition in rat Schwann cells. | Front Cell Neurosci | 2023 | https://conductscience.org/library/papers/37645595 | PubMed |
| 37626933 | Protein Kinase C at the Crossroad of Mutations, Cancer, Targeted Therapy and Immune Response. | Biology (Basel) | 2023 | https://conductscience.org/library/papers/37626933 | PubMed |
| 36358843 | Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36358843 | PubMed |
| 36200956 | Aberrant phosphorylation inactivates Numb in breast cancer causing expansion of the stem cell pool. | J Cell Biol | 2022 | https://conductscience.org/library/papers/36200956 | PubMed |
| 35707351 | Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux. | Front Oncol | 2022 | https://conductscience.org/library/papers/35707351 | PubMed |
| 35412850 | Overarching roles of diacylglycerol signaling in cancer development and antitumor immunity. | Sci Signal | 2022 | https://conductscience.org/library/papers/35412850 | PubMed |
| 35267413 | Targeting Protein Kinase C for Cancer Therapy. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35267413 | PubMed |
| 34826547 | PKCθ-mediated serine/threonine phosphorylations of FAK govern adhesion and protrusion dynamics within the lamellipodia of migrating breast cancer cells. | Cancer Lett | 2022 | https://conductscience.org/library/papers/34826547 | PubMed |
| 34622926 | PKC-ε regulates vesicle delivery and focal exocytosis for efficient IgG-mediated phagocytosis. | J Cell Sci | 2021 | https://conductscience.org/library/papers/34622926 | PubMed |
| 34433666 | TRIM47 activates NF-κB signaling via PKC-ε/PKD3 stabilization and contributes to endocrine therapy resistance in breast cancer. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/34433666 | PubMed |
| 33490232 | Unravelling Structure, Localization, and Genetic Crosstalk of KLF3 in Human Breast Cancer. | Biomed Res Int | 2020 | https://conductscience.org/library/papers/33490232 | PubMed |
| 31648598 | PKCε regulates Rho GTPases and actin cytoskeleton reorganization in non-small cell lung cancer cells. | Small GTPases | 2021 | https://conductscience.org/library/papers/31648598 | PubMed |
| 31360197 | Inhibition of protein kinase C activity inhibits osteosarcoma metastasis. | Arch Med Sci | 2019 | https://conductscience.org/library/papers/31360197 | PubMed |
| 30988374 | Differential Regulation of Gene Expression in Lung Cancer Cells by Diacyglycerol-Lactones and a Phorbol Ester Via Selective Activation of Protein Kinase C Isozymes. | Sci Rep | 2019 | https://conductscience.org/library/papers/30988374 | PubMed |
| 30923343 | Distinctive requirement of PKCε in the control of Rho GTPases in epithelial and mesenchymally transformed lung cancer cells. | Oncogene | 2019 | https://conductscience.org/library/papers/30923343 | PubMed |
| 30658316 | Claudin 1 Is Highly Upregulated by PKC in MCF7 Human Breast Cancer Cells and Correlates Positively with PKCε in Patient Biopsies. | Transl Oncol | 2019 | https://conductscience.org/library/papers/30658316 | PubMed |
| 30272339 | Identification of a novel biomarker in tangeretin‑induced cell death in AGS human gastric cancer cells. | Oncol Rep | 2018 | https://conductscience.org/library/papers/30272339 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
| PRKCE | 5581 | PubTator's text mining | https://conductscience.org/library/genes/5581 | NCBI Gene |
| RHOC | 389 | PubTator's text mining | https://conductscience.org/library/genes/389 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16166314
GET https://conductscience.org/api/papers/v1/16166314/cited_by?page=2